Could a transplant drug tame stubborn low platelets in antiphospholipid syndrome?

NCT ID NCT06722586

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This trial tests whether sirolimus (rapamycin), an immune-suppressing drug, can safely raise platelet counts in people with antiphospholipid antibodies and persistent low platelets. Participants are randomly assigned to receive sirolimus or a placebo for six months, and those who do not respond may receive sirolimus for an additional three months. The main goal is to see if sirolimus leads to a meaningful increase in platelet levels compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Sirolimus (rapamycin)
What this could lead to
If it works, sirolimus could offer a new, steroid-sparing option to manage low platelet counts in people with antiphospholipid antibodies.
What could go wrong
This is a Phase 4 trial with 84 participants. Sirolimus may not improve platelet counts more than placebo, and side effects like mouth sores, infections, or high cholesterol are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID (APL)-POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Chao-Yang Hospital

    RECRUITING

    Beijing, 100020, China

  • Beijing Shijitan Hospital

    RECRUITING

    Beijing, China

  • Peking University First Hospital

    RECRUITING

    Beijing, 100034, China

  • Peking University Third Hospital

    RECRUITING

    Beijing, 100083, China

  • People's Hospital of Xinjiang Uygur Autonomous Region

    RECRUITING

    Ürümqi, Xinjiang, 830001, China

  • Qilu Hospital of Shandong University

    RECRUITING

    Jinan, Shangdong, 250012, China

  • Shanghai Renji Hospital

    RECRUITING

    Shanghai, 200001, China

  • The 1st Affiliated Hospital of Wenzhou Medical University

    RECRUITING

    Wenzhou, Zhejiang, 325015, China

  • West China Hospital, Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

  • Xiangya Hospital of Central South University

    RECRUITING

    Changsha, Hunan, 410013, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.